13621079267 Sofosbuvir effect in India Purchasing agent of Sofosbuvir in India

,) ! / ,
,) / ' h', After buying sofosbuvir, many hepatitis C patients don’t know the specific efficacy. A few days ago, a friend of the patient was classified as hepatitis C type. Because most of the data only describe the treatment of hepatitis C with ribavirin, there is no specific data. Today, Pharmaceutical Postage will announce the recommended dosage and data for the combination of sofosbuvir and ribavirin. Provide reference for all patients and friends.
dd ,) dd dh / ' h', dd , drug delivery
Remind all patients to take medications under the guidance of the attending physician.
dd ,) dd dh / ' h', dd Patients with genotype/type hepatitis C virus infection have better response to longer courses of pegylated interferon h (h) + ribavirin. poor, and there are currently no alternative treatments.
dd ,) dd dh / ' h', dd To this end, the researchers reported the results of a phase III clinical trial called , which was designed to evaluate the efficacy of br (, m/d in previously treated patients with genotype H infection ) + Ribavirin (~m/d) treatment week or week of efficacy.
dd ,) dd dh / ' h', dd This was a randomized, placebo-controlled, double-blind study in which patients with genotype H infection were randomized to receive + weeks of treatment and to continue placebo + Placebo treatment week or + treatment week (stratified by cirrhosis and H genotype).
dd ,) dd dh / ' h', dd , the results show that patients received randomized treatment: % patients were male, % patients were white, the average age was years (range: ~ years), % Patients were genotyped, % of patients had compensated cirrhosis, % of patients had genotype H infection, and % of patients had relapse or breakthrough after previous treatment. All subjects completed treatment and received follow-up visits.
dd ,) dd dh / ' h', dd , No patient experienced virological failure
. Patients (%) discontinued treatment due to adverse events. Patients (%) experienced treatment-related serious adverse events. In terms of safety data, the incidence rate of laboratory abnormalities above Grade 1 (including Grade 1) caused by treatment is %, including blood glucose >m/d (%), lymphocytes m/d (%).
dd ,) dd dh / 'h', dd , In summary
Patients with genotype/treated H infection who received + treatment for weeks or weeks were well tolerated.